Everolimus Tablet, For Suspension
Product Images NDC 51991-990

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 51991-990). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Everolimus 01)

Chemical structure diagram of everolimus, showing its detailed molecular framework including multiple rings, hydroxyl groups, and other functional groups characteristic of the compound.*

FDA Label Image

Figure 4 (Everolimus 02)

A Kaplan-Meier curve chart comparing progression-free survival probability over time in months for Everolimus 10 mg plus exemestane versus placebo plus exemestane. It includes hazard ratio, confidence interval, and logrank p-value, with data points and censoring times marked for each group.*

FDA Label Image

Figure (Everolimus 03)

A Kaplan-Meier survival curve comparing the probability of an outcome over time in months between Everolimus-treated patients and a placebo group. The graph shows higher probabilities sustained longer with Everolimus (black line) than with placebo (dotted line). Censoring times and hazard ratio details are included on the chart.*

FDA Label Image

Figure (Everolimus 04)

A Kaplan-Meier survival curve comparing the probability of event-free status over time (in months) between Everolimus plus best supportive care (BSC) and Placebo plus BSC. The graph shows event-free probabilities on the vertical axis and time in months on the horizontal axis, with patient risk numbers at various time points below the x-axis.*

FDA Label Image

Principal Display Panel (2.5 mg Blister Pack Carton)

A Kaplan-Meier survival curve comparing the probability of survival over time (in months) for Everolimus tablets versus placebo. The graph displays separate lines for Everolimus (N=277) and placebo (N=139), with indicated censoring times and median survival durations of 4.9 months for Everolimus and 1.9 months for placebo. Hazard ratio and p-value are also noted.*

FDA Label Image

Principal Display Panel (5 mg Blister Pack Carton)

An instructional illustration showing hands peeling a label or adhesive strip from its backing. The image depicts the correct way to remove a divided adhesive label or protective film by folding and pulling it apart.*

FDA Label Image

Principal Display Panel (7.5 mg Blister Pack Carton)

An instructional line drawing showing a hand peeling back a protective layer from a tablet blister pack to access the tablet inside. The image is a general demonstration of how to open a blister pack for oral tablets.*

FDA Label Image

Principal Display Panel (10 mg Blister Pack Carton)

Everolimus Tablets 2.5 mg oral tablets packaging label from Breckenridge Pharmaceutical, Inc. The carton contains 28 tablets, arranged in 4 individual blister cards of 7 tablets each. The label includes storage instructions, manufacturer details (Natco Pharma Limited, India), and barcode information.*

FDA Label Image

Everolimus 09

Packaging label for Everolimus Tablets 5 mg by Breckenridge Pharmaceutical, Inc. The carton holds 28 oral tablets, each containing 5 mg of everolimus. The label includes storage instructions, manufacturer Natco Pharma Limited in India, distributor details, and a barcode. The box mentions the prescription-only status and blister pack configuration.*

FDA Label Image

Everolimus 10

Packaging label for Everolimus Tablets, each containing 7.5 mg of everolimus. The label indicates the product is distributed by Breckenridge Pharmaceutical, Inc. and manufactured by Natco Pharma Limited in India. The carton contains 28 tablets in four individual blister cards. Storage instructions and contact information are also included on the label.*

FDA Label Image

Everolimus 11

Packaging label for Everolimus Tablets, each containing 10 mg of everolimus. The label shows the product name, strength, quantity (28 tablets), and directions for oral use. Manufactured by Natco Pharma Limited, India, and distributed by Breckenridge Pharmaceutical, Inc. The label includes storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.